• InterView
• Sanofi introduces digital solutions for customers & patients
• by Eo, Yun-Ho Feb 22, 2022 05:55am

• Policy
• Keytruda to be reimbursed as first-line treatment for NSCLC
• by Lee, Tak-Sun Feb 22, 2022 05:54am

• Company
• Endless evolution of cancer immunotherapy
• by Eo, Yun-Ho Feb 22, 2022 05:54am

• Company
• Samsung Bioepis' biosimilar had ₩1.5 trillion
• by Chon, Seung-Hyun Feb 22, 2022 05:54am

• Company
• Kymriah is expected to be able to register insurance benefit
• by Eo, Yun-Ho Feb 21, 2022 05:59am

• Price of ‘Vesicare’ drops below its generics
• by Lee, Tak-Sun Feb 21, 2022 05:58am

• Policy
• Required PMS case reports reduced for Genvoya and Descovy
• by Lee, Hye-Kyung Feb 21, 2022 05:58am

• Policy
• Pre-registration of Novavax vaccination will begin
• by Kim, Jung-Ju Feb 21, 2022 05:58am

• Company
• Development of Xolair biosimilars is in full swing
• by Ji Yong Jun Feb 21, 2022 05:58am

• Company
• Vitrakvi's price negotiation has been extended
• by Eo, Yun-Ho Feb 18, 2022 05:55am